JETREA®, brief history

Brief history

1998 (Dec)	D. Collen founds ThromboGene Ltd (later ThromboGenics Ltd) in Ireland for R&D of cardiovascular/oncology /ophthalmology programs in-licensed from KU Leuven/VIB. Financed primarily with t-PA royalty rights (71 million Euro over the next 7 years).
1998-on	Research on treatment of ischemic stroke by N. Nagai and D. Collen in CMVB / KU Leuven leading to the concept of recombinant microplasmin.
2000	Production of microplasmin for stroke treatment by Y. Laroche and D. Collen in CMVB / KU Leuven in collaboration with Thromb-X / ThromboGenics Ltd.
2001-on	Preclinical development of microplasmin for PVD (posterior vitreous detachment) in collaboration with M. de Smet, A. Gandorfer, J.M. Stassen, M. Trese, G. Williams and NuVue.
2004-on	Clinical development of ocriplasmin for symptomatic VMA (vitreomacular adhesion), directed by S. Pakola.
2006 (Jul)	IPO of ThromboGenics NV on Euronext Brussels (35 million Euro raised).
2006 (Aug)	C. Buyse joins ThromboGenics as CFO. In the following years the Company will raise 204 million euro through four successive private placements to enable the further development of microplasmin / ocriplasmin / JETREA® among other projects.
2007 (Feb)	P. De Haes joins as COO
2008-on	Following successful completion of the Phase II MIVI trials, the MIVI-trust pivotal Phase III trials are carried out both in the US and in Europe.
2008 (Aug)	At the request of D. Collen, P. De Haes succeeds him as CEO for the day to day management of ThromboGenics NV.
2011	The MIVI-Trust Phase III program is completed successfully and published in the New England Journal of Medicine in August 2012.
2012	The company obtains pre-marketing approval for JETREA® by the FDA in the USA, where it will be marketed by ThromboGenics, Inc. For marketing in the rest of the world, JETREA® is out-licensed to Alcon / Novartis.
2013 (Jan)	US launch of JETREA® The company obtains a positive CHMP opinion for JETREA® for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
2013 (March)	European Commission approves JETREA® (ocriplasmin) in the European Union for the treatment of vitreomacular

	traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. ThromboGenics NV enters the Bel 20 index.
2013 (Apr)	ThromboGenics' JETREA® launched in the UK by partner Alcon, first market in EU
2013 (May)	JETREA® launch in Germany in private and public market by partner Alcon. Launch of JETREA® in Denmark and Sweden by Alcon.

Academic origins

The successful development of JETREA®, a first-in-class medicine for the treatment of symptomatic vitreomacular adhesion (VMA), by a Belgian start-up biopharmaceutical Company, from an initial laboratory concept to an approved biopharmaceutical product forms the pinnacle of the career in academic, translational and clinical research and development of Désiré Collen, Founder, former CEO and Chairman of ThromboGenics NV.

This development was only possible with major initial financing by the founder via his t-PA royalties, productive arms' length collaborations with KU Leuven and VIB, pragmatic adaptation and reorientation of ThromboGenics' translational research, and a stimulating business environment created by the regional government. These major achievements required the concerted efforts of a multidisciplinary Executive Committee of senior collaborators.